PARIS, Nov. 8, 2018 /PRNewswire/ -- Ipsen (France: IPN, OTC Pink: IPSEY) based in Paris, and focused on Specialty Care biopharmaceuticals, today announced that Eugenia Litz, Vice President of Investor Relations, will present at the dbVIC - Deutsche Bank American Depositary Receipt (ADR) Virtual Investor Conference on November 15, 2018. This virtual investor conference is aimed exclusively at introducing global companies with ADR programs to investors.
DATE: November 15, 2018
TIME: 9:00 AM ET
LINK: https://tinyurl.com/111415dbvicprepr
This will be a live, interactive online event where investors are invited to ask international companies their questions in real-time and to download a company's information in their "virtual trade booth" in the Exhibits section. If attendees are not able to join the event live on the day of the conference, an on-demand archive will be available for 90 days.
Participation is free of charge.
It is recommended that investors pre-register to save time and receive event updates.
About Ipsen
Ipsen is a global specialty-driven biopharmaceutical group focused on innovation and specialty care. The group develops and commercializes innovative medicines in three key therapeutic areas - Oncology, Neuroscience and Rare Diseases. Its commitment to Oncology is exemplified through its growing portfolio of key therapies for prostate cancer, neuroendocrine tumors, renal cell carcinoma and pancreatic cancer. Ipsen also has a well-established Consumer Healthcare business. With total sales over €1.9 billion in 2017, Ipsen sells more than 20 drugs in over 115 countries, with a direct commercial presence in more than 30 countries. Ipsen's R&D is focused on its innovative and differentiated technological platforms located in the heart of the leading biotechnological and life sciences hubs (Paris-Saclay, France; Oxford, UK; Cambridge, US). The Group has about 5,400 employees worldwide. Ipsen is listed in Paris (Euronext: IPN) and in the United States through a Sponsored Level I American Depositary Receipt program (ADR: IPSEY). For more information on Ipsen, visit www.ipsen.com.
SOURCE Ipsen
